[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658127":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":21,"armGroups":22,"interventions":28,"overallOfficials":17,"centralContacts":34,"locations":17,"responsibleParty":40,"collaborators":17,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":17,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":17,"studyType":55,"phases":17,"briefSummary":56,"conditions":57,"keywords":17,"overallStatus":59,"whyStopped":17,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":17},{"fullName":5,"class":6},"Lakefront Biotherapeutics West LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Participants With Adverse Events","Incidence, severity, seriousness, and frequency of adverse events.","From study entry through Week 52",[14],{"measure":15,"description":16,"timeFrame":12},"Anti-Drug Antibodies to Gamgertamig","Incidence, prevalence, and titers of anti-drug antibodies.",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","Adults who completed treatment and continue to demonstrate a clinical response in an eligible parent gamgertamig study.",[23],{"label":24,"type":17,"description":25,"interventionNames":26},"Participants Previously Treated With Gamgertami","Participants who completed an eligible parent gamgertamig study",[27],"Other: Observational",[29],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":17},"OTHER","Observational","Prior treatment with gamgertamig in an eligible parent study. No gamgertamig is administered in this follow-up study.",[24],[35],{"name":36,"role":37,"phone":38,"phoneExt":17,"email":39},"Study Sponsor","CONTACT","415-429-4887","clinicaltrials@lakefrontbio.com",{"type":41,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100658127","long-term-follow-up-study-of-gamgertamig-100658127",false,"NCT07847892","Long-Term Follow-Up Study of Gamgertamig","A Multicenter, Long-Term Follow-Up Study in Participants Who Previously Participated in a Gamgertamig (OM336) Parent Clinical Study","Inclusion Criteria:\n\n* Completed the protocol-defined treatment regimen in an eligible parent gamgertamig study.\n* Achieved and continues to demonstrate a clinical response.\n* Able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Not applicable.","ALL","18 Years","75 Years",{"count":53,"type":54},100,"ESTIMATED","OBSERVATIONAL","This study will follow adults who previously received gamgertamig in another clinical study to evaluate long-term safety and clinical outcomes.",[58],"Autoimmune Cytopenias","NOT_YET_RECRUITING","2026-09-23",{"date":62,"type":63},"2026-09-29","ACTUAL",{"date":65,"type":54},"2026-10",{"date":67,"type":54},"2029-12",{"name":5,"class":6}]